Medicaments

Abstract

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

1 - 17 . (canceled) 
   
   
       18 . A pharmaceutical aerosol formulation comprising particulate medicament which is fluticasone propionate or a physiologically acceptable solvate thereof, and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant, which formulation is essentially free of surfactant and free of chlorofluorocarbons, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size not less than 100 microns. 
   
   
       19 . The formulation according to  claim 18 , wherein the particle size of substantially all of the fluticasone propionate is less than 20 microns. 
   
   
       20 . A canister comprising a container having the pharmaceutical aerosol formulation according to  claim 18  contained therein. 
   
   
       21 . The canister according to  claim 20 , wherein the canister is an aluminum can. 
   
   
       22 . A canister according to  claim 21  wherein the container is plastics-coated, lacquer coated or anodized. 
   
   
       23 . A metered dose inhaler which comprises a canister according to  claim 20  fitted into a suitable channeling device.